PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the publication of four abstracts in the Journal of Dental Sleep Medicine. The abstracts can be found at https://aadsm.org/journal/abstracts_issue_102.php.
These data will be presented in oral and poster presentations at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, being held from May 19-21 in Philadelphia, Pennsylvania.
Titles of the accepted abstract presentations at AADSM are as follows:
| Title | Precision Vs. Traditional Oral Appliance Therapy: a Comparison of Therapeutic Efficacy |
| Abstract Number | 006 |
| Title | Comparison of Clinical Effectiveness And Patients’ Preference for Two Non-invasive Treatment Options for Patients Diagnosed with Moderate to Severe Obstructive Sleep Apnea: The FLOSAT Study |
| Abstract Number | 008 |
| Title | OAT Device Designs are Not the Same When It Comes to FDA Adverse Event Reports |
| Abstract Number | 011 |
| Title | Adverse Event Reports for Continuous Positive Airway Pressure, Hypoglossal Nerve Stimulation and Oral Appliance Therapy Devices: an FDA MAUDE Database Analysis |
| Abstract Number | 012 |
About ProSomnus
ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 200,000 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.
Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Elizabeth Coleman
ICR Westwicke
Phone: +1.203.682.4783
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.47 |
| Daily Volume: | 0 |
| Market Cap: | US$8.170M |
March 15, 2024 February 22, 2024 December 19, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
